secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001437749-24-001469
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree licenses cardio drugs to Lee's for up to $138M milestones; PM deals restructured
--------------------------------------------------------------------------------

- Lee's gets exclusive rights to istaroxime, rostafuroxin, SERCA2a activators in 14 Asian countries for heart failure and cardiogenic shock.
- Windtree eligible for up to $3.1M in pre-development/regulatory milestones and $135.25M in sales milestones, plus low double-digit sublicense income.
- Tiered royalties from low single-digit to low double-digit on net sales, subject to reduction by up to 50% under generic competition.
- PM USA/PMPSA amendments: Windtree pays $500k fixed plus $1.4M milestones, extinguishes quarterly payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/0001437749-24-001469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924001469/wint20240116_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer